Inside a diseased cell, the genes are in chaos. Some are receiving signals to overproduce a protein. Others are reducing ...

Welcome to Brii Bio's 2025 Full Year Financial Results and Corporate Update Conference Call. Our annual result announcements can be found on the Investor Relations section of our company website.

Discover how CRISPR genome editing is revolutionizing medicine. Learn the science of Cas9, current clinical trials, and the future of gene editing.

Commercialization ready compound supports a new method of generating highly functional human CAR-T cells for treating infectious diseases and cancer ...

Foundational research led by co-founder Justin Eyquem, Ph.D., underpins Azalea's proprietary in vivo CAR T platform -- Peer-reviewed publication demonstrates stable, cell-specific transgene expression ...

Dr. Rasha Kelej Continues to Advance Cancer Care in Africa by Providing 269 Oncology Scholarships for 34 African Countries and Beyond ...

The Food and Drugs Authority (FDA) has issued an urgent public alert following the discovery of a dangerous, unregistered substance being sold under the name ‘Sukudai’.

Institutional Collaboration Across Stakeholders, fostering shared governance and aligned incentives among payers, providers, and life sciences partners.

Cuts, gaps, and inequities in global cancer research funding are calling out for philanthropy itself to be cured Medical philanthropy likes to debate money.  How much is needed, how it’s distributed, ...

Advanced research and development of CUE-401 for IND (Investigational New Drug) readiness -CUE-401 is the Company's lead asset for the treatment of autoimmune and inflammatory diseasesAppointed indust ...

Commercialization ready compound supports a new method of generating highly functional human CAR-T cells for treating infectious diseases and cancer In experimental models, human CAR-T cells manufactu ...